Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
IRCT20190122042450N3Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM), sponsored by Iran University of Medical Sciences. Started May 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20190122042450N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190122042450N3.